This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we will discuss yet another endothelin antagonist trial, on a background of flozins, in proteinuric CKD. Will flozins help breakthrough the endothelin badness?
This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?
This week, we will discuss the first new BP lowering drug in decades. Aprocitentan, a dual endothelin antagonist in a meticulously designed trial in resistant hypertension.
This week, we will discuss The ADVOR trial, possibly the only randomized, placebo controlled trial of sequential nephron blockade ever. Could the use of acetazolamide in acute decompensated heart failure make a difference?
This week, we will discuss the CLICK trial. Another medical reversal - showing that this old and cheap drug, chlorthalidone, might actually work in advanced CKD. Click through to read more.
This week, we discuss the discovery that peritoneal membrane water transport, and PD outcomes, are influenced by genetic variations in the Aquaporin 1 channel.
This week, we will discuss the SSASS trial. in which a simple switch of table salt with a K-enriched salt works miracles. Is it about the sodium or the potassium?
As the Tour de France goes on, it is timely to discuss the role of exercise, while on dialysis. The CYCLEHD trial reported a lowering of left ventricular mass. Let’s dig deeper, as we do.
The AURORA-1 trial. Sparkling with hope for lupus nephritis. Will this make it easier for rheumatologists to prescribe a CNI? Can you overcome the sticker shock to examine the benefits and weaknesses of AURORA-1. Let’s dive in.
This week, we will discuss the ADVOCATE trial. Avacopan is not just a flash in the pan? We hope so, having won the RheumMadness and offering a steroid free hope.
This is the first, yes, the first time we are discussing a trial in SLE patients. Belimumab, which inhibits BAFF also called BLyS (hence the BLISS trials) in lupus nephritis. Added to a background of standard therapy - what does it give us? Let’s dive in.